Europe Vaccine Contract Manufacturing Market

Europe Vaccine Contract Manufacturing Market Size (2023 to 2028)

The size of the Vaccine contract manufacturing market size was about USD 199.18 million in 2023. It is expected to rise at a CAGR of 7.3% and turn into a USD 283.29 million market by 2028, primarily because of the enormous elderly population and increase in the CMO contracts in this region.

Increasing investments and funding due to the high focus of private and government bodies across the European region on the research and development of the vaccine industry, a significant revenue contributor in Europe, is a significant factor contributing to the growth of the European vaccine contract manufacturing market. Increasing treatment prevalence of infectious diseases such as influenza virus, malaria, and Hepatitis-B is another key factor that boosts the growth rate of the European vaccines contract manufacturing market. Other factors that are expected to expand the size of the European vaccines contract manufacturing market are increasing awareness among the public regarding the vaccination and emergence of a variety of vaccines into the market. Increasing focus on specialized medications with the integration of big data, IoT, and artificial intelligence is expected to boost the European vaccines contract manufacturing market during the forecast period.

The challenges that are expected to limit the growth of the market are unorganized information management systems in the region, lack of better infrastructure, shortage of manual resources, need for constant monitoring to maintain storage temperatures.

This research report on the Europe vaccine contract manufacturing market has been segmented and sub-segmented into the following categories:

By Service Type:

• Bulk Product
• Fill Finish

By Product Type:

• Single Vaccine
• Influenza Virus
• Ebola Virus
• Chickenpox
• Tetanus
• Tuberculosis
• Polio
• Smallpox
• Others
• Combination Type

By Vaccine Type:

• Inactivated Vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Synthetic Vaccines

By Country:

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe

Regionally, Europe is the second-largest market for vaccine contract manufacturing, with about 20 CMOs located in Germany, U.K., and France. MOs in these locations have gained significant ground. With increasing backing from local law authorities, many low-income geographies have updated their homegrown supervisory landscape. Patent laws have been made more challenging, favoring foreign backers viewing to farm out business operations in the same regions. Larger settled organizations in this market have also received the essential qualifications and certifications to deliver services in agreement with international standards.

In 2019, Germany had accounted for the leading shares in the European vaccines contract manufacturing market. The market share is expected to grow consistently at a high CAGR during the forecast period owing to the factors such as technological advancements and implementation of artificial intelligence and IoT for manufacturing vaccines, which are continuously transcending the vaccines manufacturing processes, increasing investments from private organizations, and focus of government funding are fuelling the market growth. The UK is another prominent revenue contributor to the European vaccines contract manufacturing market and is expected to continue this trend during the forecast period.

Notable companies leading the European vaccine contract manufacturing market profiled in this report are Thomas Jefferson University, Goodwin Biotechnology Inc., BioMARK, Emergent BioSolutions, Soligenix Inc., Catalent Biologics, Minneapolis Medical Research Foundation (MMRF), Bavarian Nordic A/S, and FUJIFILM Diosynth Biotechnologies.